João-Pierre arrived in 1997 at the door of NJBIZ, then known as Business News New Jersey, as an intern and was hired that same year as a staff writer. For more than 12 years he has covered the retail, technology, and media industries in the state. He also handles principal online news writing at NJBIZ.com. João-Pierre is a lifelong resident of the state and graduated from Rutgers University. 
Joint ventures develop new pharma products, security software preps for tax season.
North
Emisphere Technologies Inc., in the Cedar Knolls section of Hanover, said Thursday that it entered a joint agreement with Australia’s Alchemia Ltd. to develop an oral form of anti-coagulant drug fondaparinux. The joint effort will use Emisphere’s drug delivery platform called Eligen Technology. Fondaparinux is a version of the off-patent Arixtra injection marketed by GlaxoSmithKline. Alchemia’s marketing partner, Dr Reddy’s Laboratories, filed an abbreviated new drug application for a generic version of the injection form of fondaparinux with the U.S. Food and Drug Administration.
Central
StrikeForce Technologies Inc., in Edison, said Thursday its GuardedID keystroke encryption software is being promoted by Sweden’s Lavasoft as part of a tax season protection software bundle.
South
Nuvilex Inc., in Cherry Hill, said Thursday that its joint-venture partner, Legacy Biotechnologies Inc., began production of Reme-Flu. The product, a two-part flu remedy, is expected to be available for consumers within 30 days. Reme-Flu will be initially available through Nutralegacy.com.
E-mail João-Pierre Ruth at jpruth@njbiz.com
Follow me on Twitter @jpruth
